Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, drug resistance remains the major obstacle causing treatment failure in clinical practice. Here, we investigated the effects of Indirubin-3’-monoxime (I3MO), one of the derivatives of Indirubin, in the treatment of MM. MM patient primary samples and human cell lines were examined. I3MO effects on myeloma treatment and the underling molecular mechanisms were investigated via in vivo and in vitro study. Our results demonstrated the anti-MM activity of I3MO in both drug- sensitive and -resistance MM cells. I3MO sensitizes MM cells to bortezomib-induced apoptosis. Mechanistically, I3MO acts as a multifaceted regulator of cell death, which induced DNA damage, cell cycle arrest, and abrogates NF-κB activation. I3MO efficiently down-regulated USP7 expression, promoted NEK2 degradation, and suppressed NF-κB signaling in MM. Our study reported that I3MO directly bound with and caused the down-regulation of PA28γ (PSME3), and PA200 (PSME4), the proteasome activators. Knockdown of PSME3 or PSME4 caused the inhibition of proteasome capacity and the overload of paraprotein, which sensitizes MM cells to bortezomib-mediated growth arrest. Clinical data demonstrated that PSME3 and PSME4 are over-expressed in relapsed/refractory MM (RRMM) and associated with inferior outcome. Altogether, our study indicates that I3MO is agent triggering proteasome inhibition and represents a promising therapeutic strategy to improve patient outcome in MM. A full list of funding can be found in the acknowledgements.
3 May 2021 in Journal of Cellular and Molecular Medicine
Tumour radioresistance is a major problem for cancer radiation therapy. To identify the underlying mechanisms of this resistance, we used human non‐small cell lung cancer (NSCLC) cell lines and focused on the Inhibitor of Apoptosis Protein (IAP) family, which contributes to tumourigenesis and chemoresistance. We investigated the possible correlation between radioresistance in six NSCLC cell lines and IAP protein levels and tested the radiosensitizing effect of birinapant in vitro, a molecule that mimics the second mitochondria‐derived activator of caspase. We found that birinapant‐induced apoptosis and inhibited the proliferation of NSCLC cells after exposure to radiation. These effects were induced by birinapant downregulation of cIAP protein levels and changes of cIAP gene expression. Overall, birinapant can inhibit tumour growth of NSCLC cell lines to ironizing radiation and act as a promising strategy to overcome radioresistance in NSCLC.
Oral exposure to nanoplastics (NPs) adversely affects mammalian health, yet the mechanisms driving distal pulmonary toxicity remain poorly understood. Specifically, how different NP polymers disrupt the gut–lung–microbiota axis is largely elusive. This study investigated the effects of 12-week oral exposure to three common NPs [polystyrene (PS), polypropylene (PP), and polyethylene (PE)] at environmentally relevant doses (50 μg/d and 500 μg/d) in a murine model, followed by histopathological, microbiomics, and metabolomic analyses to delineate NP-induced alterations in intestinal and pulmonary tissues. Results revealed that all three NPs compromised intestinal barrier integrity through disruption of tight junction proteins, concomitant with marked histopathological alterations and inflammatory infiltration in pulmonary tissues. Among them, PE-NPs provoked the most severe pulmonary inflammation and fibrotic progression. Analysis of the lung microbiome revealed significant shifts in the relative abundance of specific bacterial taxa, where high-dose PE induced the ectopic lung colonization of gut-associated bacteria (e.g., Turicibacter), providing direct evidence of barrier breach and distal dysbiosis. Notably, pulmonary enrichment of Stenotrophomonas and Sphingomonas correlated strongly with inflammatory metabolites (e.g., dehydroabietic acid), suggesting microbiota-driven metabolic reprogramming in the lung. Collectively, our findings establish that oral NP ingestion initiates a pathogenic cascade where gut barrier failure enables cross-organ microbial translocation and metabolic dysregulation, ultimately exacerbating pulmonary fibrosis. This study provides crucial mechanistic insights into the material-specific, distal toxicity of ingested NPs.